LGND - Ligand Pharmaceuticals: Solid Performer Performing Solidly

2024-07-29 14:43:00 ET

Summary

• Ligand Pharmaceuticals has seen over a 50% increase in share value since its Q1 earnings report.
• Recent positive developments include new deals, regulatory successes, and raising 2024 guidance.
• A new deal of close to $200 million with Agenus and $100 million acquisition of APEIRON contribute to the positive outlook.

This is my seventh article on a long-time favorite, Ligand Pharmaceuticals ( LGND ), following most recently 04/2024's "Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio" (" Growth "). In Growth, I rated Ligand as a "Buy". It has rewarded its shareholders in the interim with a nice >50% increase....

For further details see: